RIGL Q3 2022 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+4.0% YoY

Gross Profit

$22M98.9% margin

Operating Income

-$18M-82.1% margin

Net Income

-$19M-84.9% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-24.8%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$116M

Total Liabilities

$135M

Stockholders' Equity

-$20M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$22M	+4.0%
Gross Profit	$22M	$21M	+3.6%
Operating Income	-$18M	-$20M	+7.0%
Net Income	-$19M	-$21M	+9.1%

Revenue Segments

Gross product sales

$27M64%

Product sales, net

$19M45%

Government contract

$3M6%

Revenues from collaborations

$722,0002%

Research and development services and others

$722,0002%

Discounts and allowances

-$8M-18%